References

Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis

10.1001/jamaoncol.2023.4837 · 2024 · External reference

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

10.1016/s0140-6736(15)61074-1 · 2015 · External reference

Unresolved reference

External reference

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

10.1016/s1470-2045(22)00694-5 · 2023 · External reference

Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

10.1200/jco.23.01994 · 2024 · External reference

Ribociclib plus endocrine therapy in early breast cancer

10.1056/nejmoa2305488 · 2024 · External reference

Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03)

10.1200/jco.21.02554 · 2022 · External reference

Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the PENELOPE-B trial

10.1200/jco.20.03639 · 2021 · External reference

Ribociclib plus endocrine therapy in hormone receptor-positive/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial

10.1001/jamaoncol.2025.3700 · 2025 · External reference

Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan

10.1080/14796694.2024.2346464 · 2024 · External reference

Real-world experience of abemaciclib for adjuvant and metastatic breast cancer

10.1177/10781552241279189 · 2025 · External reference